Specialities

Specialities

COVID-19
Anaemia
Leukaemia
Myeloproliferative Disorders
Haematological Malignancies
Myelodysplastic Syndrome
Paediatric Haematology
Rare Diseases
Thrombocytopenia
Genetic Blood Disorders
Amyloidosis
Autoimmune Blood Disorders
Blood and Bone Marrow Transplantation
Haemostatic Disorders
Lymphoma
Myeloma
Search

Trending Topic

Acute myeloid leukaemia
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Drug development in acute myeloid leukaemia picks up pace

touchHAEMATOLOGY

“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were an estimated 21,450 new patients with acute myeloid leukaemia (AML) and 11,180 AML-related deaths […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

CME Accredited Learning

Our accredited content is designed to impact patient health outcomes, by ensuring that it provides you with a learning experience that will positively impact your clinical practice, based on adult learning preferences and intuitive instructional design. All activities are developed in collaboration with leading faculty and education partners.

touchHAEMATOLOGY

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
55 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024

Prof. María-Victoria Mateos, Dr Rakesh Popat, Prof. Evangelos Terpos

Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.

Translations available:
51 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchCONGRESS

Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?

Dr Vickie McDonald, Prof. Waleed Ghanima, Prof. James B Bussel

Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.

Translations available:
39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma: From optimal sequencing to shared decision-making

Dr Matthew Lunning, Professor Charalambos Andreadis, Dr Tara Graff

Haematology experts discuss the latest on novel therapies and treatment selection and sequencing in R/R FL

Translations available:
52 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management

Prof. Dr Vito Sabato, Dr Sigurd Broesby-Olsen, Prof. Prithviraj Bose

Multidisciplinary experts discuss the diagnosis and management of patients with systemic mastocytosis.

Translations available:
48 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT

Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team

Prof. Michael Jordan, Dr Kate Kernan, Dr Eric Gars, Prof. Rob MacLaren

Multidisciplinary experts discuss the diagnosis and management of haemophagocytic lymphohistiocytosis (HLH)

Translations available:
32 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS

The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials

Prof. Cristina Gasparetto, Prof. Sagar Lonial, Prof. Sundar Jagannath

Learn about investigational protein degradation and immunomodulatory therapies in multiple myeloma.

Translations available:
41 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

Managing the practicalities of CAR T-cell therapies in patients with R/R MCL: Current considerations and future strategies

Dr Matthew Matasar, Dr Amitkumar Mehta

Watch haemato-oncology experts discuss updates in managing R/R mantle cell lymphoma with CAR T-cell therapy.

Translations available:
39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

New horizons in R/R follicular lymphoma: Focus on risk stratification and managing the practicalities of CAR T-cell therapy

Dr Nilanjan Ghosh, Dr Peter Riedell

Watch haemato-oncology experts discuss updates in R/R follicular lymphoma, with a focus on CAR T-cell therapy.

39 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy

Prof. Biree Andemariam, Prof. Modupe Idowu, Prof. Mark C Walters

Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

Society & Congress Partners

touchHAEMATOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events

View All
38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION

Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic

Dr Raajit Rampal, Prof. John Mascarenhas

Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

38 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice

Dr Sarah Holstein, Dr Nikhil Munshi, Dr Noopur Raje

Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).

37 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?

Dr Rachael Grace, Dr Hanny Al-Samkari, Dr Ami J Shah

Three experts discuss the burden and clinical presentation of pyruvate kinase deficiency, as well as current and emerging therapeutic strategies.

34 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchTALKS

What’s on the horizon for higher-risk MDS? An update on emerging novel agents

Dr David Sallman

Dr David Sallman reviews advances in HR-MDS management, including the mode of action and latest clinical data for emerging treatments.

32 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?

Prof. Morie Gertz, Prof. Bernd Jilma, Dr Shirley D'Sa

Watch three experts discuss the pathophysiology of cold agglutinin disease (CAD) and the steps needed for an accurate diagnosis. The panel goes on to discuss how emerging treatment options are changing the management of patients with primary CAD and the importance of tailoring treatment to improve outcomes. The discussion is guided by pre-canvassed questions provided by the haematological clinical community.

36 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchPANEL DISCUSSION

Keeping pace with the evolving treatment paradigm for relapsed/refractory multiple myeloma: Earlier use of novel agents

Dr Nina Shah, Dr Cristina Gasparetto, Prof. Xavier Leleu

Three international experts discuss how novel agents approved for early lines of therapy are changing the landscape of RRMM treatment.

Load More...

All touchIME CME activities are accredited. Learners can claim ACCME, ANCC, ACPE or EBAC credits upon completion of the activities. This content is for healthcare professionals only.

Latest Medical Education - straight to your inbox

Close Popup